Scout Investments Inc. Takes Position in Eagle Pharmaceuticals Inc (EGRX)

Scout Investments Inc. purchased a new position in shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 45,022 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,121,000.

Several other institutional investors also recently made changes to their positions in EGRX. Rothschild Asset Management Inc. acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $30,835,000. BlackRock Inc. raised its position in shares of Eagle Pharmaceuticals by 14.7% during the 2nd quarter. BlackRock Inc. now owns 1,432,090 shares of the specialty pharmaceutical company’s stock worth $108,351,000 after purchasing an additional 183,287 shares during the period. Chartwell Investment Partners LLC acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $12,063,000. Granite Investment Partners LLC raised its position in shares of Eagle Pharmaceuticals by 74.0% during the 2nd quarter. Granite Investment Partners LLC now owns 198,774 shares of the specialty pharmaceutical company’s stock worth $15,039,000 after purchasing an additional 84,567 shares during the period. Finally, Sei Investments Co. raised its position in shares of Eagle Pharmaceuticals by 236.9% during the 2nd quarter. Sei Investments Co. now owns 112,279 shares of the specialty pharmaceutical company’s stock worth $8,495,000 after purchasing an additional 78,953 shares during the period.

A number of brokerages have recently weighed in on EGRX. ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. TheStreet upgraded Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. Finally, increased their price target on Eagle Pharmaceuticals to $119.00 and gave the stock a “buy” rating in a research report on Tuesday, July 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Eagle Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $86.50.

Shares of EGRX stock opened at $58.08 on Friday. Eagle Pharmaceuticals Inc has a 12-month low of $50.23 and a 12-month high of $85.66. The company has a market capitalization of $895.68 million, a P/E ratio of 26.44 and a beta of 1.32. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.22 and a quick ratio of 4.09.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.15. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. The business had revenue of $59.30 million during the quarter, compared to analyst estimates of $51.78 million. Equities research analysts forecast that Eagle Pharmaceuticals Inc will post 1.96 EPS for the current fiscal year.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Read More: What is a conference call?

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply